Form 4: ARDX Chief Patient Officer Receives Equity Awards

Laura A. Williams, Chief Patient Officer of Ardelyx, Inc., was granted 82,695 restricted stock units and options to purchase 124,040 shares of common stock.

Summary

• Laura A. Williams, Chief Patient Officer of Ardelyx, Inc. (ARDX), acquired 82,695 shares of Common Stock in the form of Restricted Stock Units (RSUs) on January 23, 2026.
• Each RSU entitles the reporting person to receive one share of Common Stock upon vesting.
• Williams also acquired options to buy 124,040 shares of Common Stock with an exercise price of $7.77 per share on January 23, 2026.
• The stock options begin vesting on January 23, 2026, and will vest in 48 successive, equal monthly installments, contingent on continued employment.
• The stock options have an expiration date of January 23, 2036.
• Following these transactions, Williams beneficially owns 444,258 shares of Common Stock (including RSUs) and 124,040 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation in the form of equity grants. This is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests, but does not provide new operational or financial performance data.

Positives

• The equity grants align the Chief Patient Officer's financial interests with those of the company's shareholders, incentivizing long-term performance.
• The grants represent a standard form of executive compensation, indicating continued commitment to retaining key management.

Negatives

• The grants do not represent an immediate cash inflow for the reporting person, as they are subject to vesting schedules.
• The value of the awards is contingent on the future performance of Ardelyx's stock price.

Risks

• The value of the granted RSUs and stock options is subject to market fluctuations of Ardelyx's common stock.
• Vesting of both the RSUs and stock options is contingent upon the reporting person's continued employment or service relationship with the Issuer, meaning forfeiture could occur if employment ceases.

Future Outlook

The equity grants serve as a long-term incentive for the Chief Patient Officer, aligning her future performance with the company's strategic goals and shareholder value creation over the vesting period.

Industry Context

Equity grants, including RSUs and stock options, are a common component of executive compensation packages in the biotechnology and pharmaceutical industries. They are designed to attract, retain, and motivate key personnel by linking their compensation to the company's long-term success and stock performance.

Comparison to Industry Standards

• The structure of these equity grants, involving both RSUs and stock options with multi-year vesting schedules, is consistent with typical executive compensation practices observed across the biotechnology and pharmaceutical sectors.
• The use of performance-based incentives like stock options and time-based incentives like RSUs is a standard approach to balancing risk and reward for executives in growth-oriented companies like Ardelyx.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants are intended to align the Chief Patient Officer's interests with those of shareholders, potentially leading to improved long-term company performance and stock value.
• Employees: The grants demonstrate the company's commitment to executive compensation, which can positively influence morale and retention of key personnel.

Next Steps

• The granted RSUs will vest over time, converting into shares of common stock.
• The granted stock options will vest in monthly installments, becoming exercisable over a 48-month period, subject to continued employment.

Key Dates

Keywords

Ardelyx, ARDX, Form 4, Insider Transaction, Equity Grant, RSU, Stock Option, Executive Compensation, Laura A. Williams, Chief Patient Officer